 Dishman Pharmaceuticals & Chemicals (DPCL) has posted disappointing results for the Q4FY10 due to 24%YoY fall in CRAMS revenues. Total income declined by 13%YoY from Rs2.89bn to Rs2.50bn due to the slowdown in Carbogen Amcis (CA) and other CRAMS business. Net profit declined by 71% from Rs717m to Rs211m.
Dishman Pharmaceuticals & Chemicals (DPCL) has posted disappointing results for the Q4FY10 due to 24%YoY fall in CRAMS revenues. Total income declined by 13%YoY from Rs2.89bn to Rs2.50bn due to the slowdown in Carbogen Amcis (CA) and other CRAMS business. Net profit declined by 71% from Rs717m to Rs211m.
The company’s EBIDTA margin improved by 560bps from 24.2% to 29.8% mainly (more…)
 In a conference call Prof. Kirit Parikh, ex-member, Planning Commission, and chairman of the expert group constituted by the Government on sustainable petroleum pricing, to share his views on the Indian energy sector and related issues in the broad economy.
In a conference call Prof. Kirit Parikh, ex-member, Planning Commission, and chairman of the expert group constituted by the Government on sustainable petroleum pricing, to share his views on the Indian energy sector and related issues in the broad economy.